-
Silencing World Cup hotshot Haaland vital, says England's O'Reilly
-
Leonard return to Raptors on hold pending Clippers probe
-
Australian sprint sensation Gout Gout set to miss rest of season
-
US pushes for weaker truck pollution rules
-
England thrash India by nine wickets for T20 series win
-
Black and cream and very Roman at Fendi haute couture show
-
Wimbledon run came 'out of nowhere', says finalist Noskova
-
Spain keeping opposition far from goal at World Cup, says 'keeper Garcia
-
India captain Kaur hopes Lord's Test can offset World Cup woes
-
Czech mates Muchova and Noskova to clash in Wimbledon final
-
China factory fire kills at least 28 people
-
Bayeux Tapestry begins epic journey from France to London: source
-
Dubai Police Unveil Next Generation of ‘Ghiath’ Smart Patrols Powered by BYD
-
King in shades braves heat to visit London zoo
-
Djokovic faces Sinner showdown, Fery eyes Wimbledon final
-
Gauff expecting hate messages after Wimbledon loss
-
Noskova books all-Czech Wimbledon final clash with Muchova
-
US star Pulisic fractured leg in Belgium loss: team
-
England's Quansah handed two-game World Cup ban
-
Pogacar, like Jordan, Bolt or Djokovic?
-
UK sets record for number of days over 34C
-
Ex-Puma Urdapilleta shuns retirement to play on at 40
-
Haaland relishing 'special' World Cup showdown with England
-
Keep me away from the pool, Kipyegon tells triathlete Beaugrand
-
FIFA lashes 'unfounded allegations' after Argentina-Egypt clash
-
Nerves high in Kyiv as Russia escalates missile attacks
-
'Only revenge': Iran mourners defiant at Khamenei burial
-
Stars pay tribute to 'Total Eclipse' singer Bonnie Tyler, who has died at 75
-
Pogacar reclaims Tour de France yellow jersey with stage six win
-
'I'm ready to roll' - hungry Duplantis still motivated
-
US existing home sales dip in June as cost worries persist
-
Muchova beats Gauff in thriller to reach first Wimbledon final
-
Russia subjecting 1.6 million Ukrainian children to military brainwashing: OSCE report
-
One revolver, six bullets: Turkish president's 'unusual' gift to NATO leaders
-
Strengthening El Nino likely to 'rank among largest' on record: US agency
-
Kicking off: New York football enthusiasts defy pitch shortage
-
Jorge Jesus to take over as Portugal coach after World Cup exit
-
Fendi shows haute couture in Rome with nod to Lagerfeld
-
Ebola outbreak is 'fastest growing ever' as 600 die
-
Olympic sprint champs Alfred, Thomas bid for work-life balance
-
Stocks shrug off tensions to rise on renewed tech interest
-
How NATO leaders reacted to Erdogan's revolver gift
-
Hong Kong welcomes dogs into restaurants, to pet owners' delight
-
Union warns of 'conflict' as Volkswagen eyes mass job cuts
-
England recall Slade for Fiji as pressure mounts on Borthwick
-
Chemical weapons watchdog reinstates Syria
-
Lock Petti to become latest Argentina centurion in Nations Championship Test
-
Cocoa lynchpin sees chocolate lovers make hesitant return
-
EU parliament greenlights digital euro
-
French yachtswoman set to break new barriers in Route du Rhum
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
J.Bergmann--BTB